Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of Th17/Treg cell differentiation and heme oxygenase 1 induction

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 874-885

  Moon, Su Jin ^a   Park, Jin Sil ^a   Woo, Yun Ju ^a   Lim, Mi Ae ^a   Kim, Sung Min ^a   Lee, Seon Yeong ^a   Kim, Eun Kyung ^a   Lee, Hee Jin ^b   Lee, Weon Sun ^b   Park, Sang Hi ^b   Jeong, Jeong Hee ^a   Park, Sung Hwan ^a   Kim, Ho Youn ^a   Cho, Mi La ^a   Min, Jun Ki ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; COLLAGEN ANTIBODY; COLLAGEN TYPE 2 ANTIBODY; HEME OXYGENASE 1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; ORPHAN NUCLEAR RECEPTOR GAMMA T; REBAMIPIDE; RETINOIC ACID RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOMA CELL LINE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; TH17 CELL; WESTERN BLOTTING;

ALANINE; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; CELL DIFFERENTIATION; CYTOKINES; HEME OXYGENASE-1; MALE; MICE; MICE, INBRED DBA; QUINOLONES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84898634958     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38310     Document Type: Article

References (38)

1. Kageyama Y, Koide Y, Yoshida A, Uchijima M, Arai T, Miyamoto S, et al. Reduced susceptibility to collagen-induced arthritis in mice deficient in IFN-γ receptor. J Immunol 1998; 161: 1542-8.
2. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963-70.
3. Hammaker D, Boyle DL, Firestein GS,. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology (Oxford) 2012; 51: 610-8.
4. Pawlowska J, Smolenska Z, Zdrojewski Z, Witkowski JM, Bryl E,. Changes in proliferation kinetics of T cells: a new predictive cellular biomarkers for early rheumatoid arthritis? J Clin Immunol 2012; 32: 991-9.
5. Alsaleh G, Sparsa L, Chatelus E, Ehlinger M, Gottenberg JE, Wachsmann D, et al. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010; 12: R135.
6. Lubberts E, Koenders MI, van den Berg WB,. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
7. Nakae S, Nambu A, Sudo K, Iwakura Y,. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
8. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y,. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003; 100: 5986-90.
9. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27.
10. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60: 2903-13.
11. Jadidi-Niaragh F, Mirshafiey A,. Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacol Immunotoxicol 2011; 33: 545-67.
12. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277-85.
13. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140: 360-7.
14. Finkel T, Holbrook NJ,. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
15. Simmons RA,. Developmental origins of diabetes: the role of oxidative stress. Best Pract Res Clin Endocrinol Metab 2012; 26: 701-8.
16. Noren Hooten N, Ejiogu N, Zonderman AB, Evans MK,. Association of oxidative DNA damage and C-reactive protein in women at risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 2012; 32: 2776-84.
17. Heliovaara M, Knekt P, Aho K, Aaran RK, Alfthan G, Aromaa A,. Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis 1994; 53: 51-3.
18. Hagfors L, Leanderson P, Skoldstam L, Andersson J, Johansson G,. Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, Mediterranean dietary intervention study on patients with rheumatoid arthritis. Nutr J 2003; 2: 5.
19. Blake DR, Merry P, Unsworth J, Kidd BL, Outhwaite JM, Ballard R, et al. Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1989; 1: 289-93.
20. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P,. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 36-43.
21. Peng S, Duggan A,. Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf 2005; 4: 157-69.
22. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC,. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 21-4.
23. Gabriel SE, Jaakkimainen L, Bombardier C,. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96.
24. Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 1995; 18: 117-23.
25. Kobayashi T, Zinchuk VS, Garcia del Saz E, Jiang F, Yamasaki Y, Kataoka S, et al. Suppressive effect of rebamipide, an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl- phenylalanine. Histol Histopathol 2000; 15: 1067-76.
26. + pathogenic T cell in autoimmune arthritis. Immunol Lett 2011; 135: 50-8.
27. Choy E,. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 5: v3-11.
28. Kaspar JW, Niture SK, Jaiswal AK,. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009; 47: 1304-9.
29. pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-52.
30. + T cells. J Exp Med 2008; 205: 1381-93.
31. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, et al. Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008; 76: 1485-9.
32. Ruan Q, Chen YH,. Nuclear factor-κB in immunity and inflammation: the Treg and Th17 connection. Adv Exp Med Biol 2012; 946: 207-21.
33. Wallace JL,. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol 2012; 165: 67-74.
34. Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58: 1991-2000.
35. Goldstein JL, Cryer B, Amer F, Hunt B,. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5: 1167-74.
36. Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, et al. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis 2010; 13: 151-7.
37. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8.
38. Hasegawa M, Horiki N, Tanaka K, Wakabayashi H, Tano S, Katsurahara M, et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol 2013; 23: 1172-8.